SAN FRANCISCO--(BUSINESS WIRE)--Theregen, Inc. today announced a second Phase I trial to examine the role of its Anginera™ cell-based cardiovascular heart patch on adult patients suffering from heart disease. Surgeons from the University of Pennsylvania and University of Maryland have successfully placed study patches, including Anginera, on the surface (epicardium) of diseased hearts of patients suffering from Stage D Heart Failure (HF). Each patient also received an implanted left ventricular assist device (LVAD) while waiting for a donated heart at some future date. When the study patients later receive a transplanted heart, their removed, diseased heart will be analyzed to determine the effect of Anginera on heart tissue. The Anginera patch contains human fibroblast cells that secrete multiple biochemical factors essential to forming blood vessels and aiding in tissue repair.
